학술논문
Treatment of induced oligometastatic disease after partial response to immunochemotherapy in patient with stage IV non-small cell lung cancer and severe toxicity.
Document Type
Academic Journal
Author
Mughal HA; Department of Oncology and Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.; Mouritzen MT; Department of Oncology and Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.; Department of Clinical Medicine, Faculty of Medicine, Aalborg University, Aalborg, Denmark.; Takacs-Szabó Z; Department of Radiology, Aalborg University Hospital, Aalborg, Denmark.; Szejniuk WM; Department of Oncology and Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark wszejniuk@gmail.com.; Department of Clinical Medicine, Faculty of Medicine, Aalborg University, Aalborg, Denmark.
Source
Publisher: BMJ Pub. Group Country of Publication: England NLM ID: 101526291 Publication Model: Electronic Cited Medium: Internet ISSN: 1757-790X (Electronic) Linking ISSN: 1757790X NLM ISO Abbreviation: BMJ Case Rep Subsets: MEDLINE
Subject
Language
English
Abstract
Treatment of induced oligometastatic disease after partial response to systemic antineoplastic therapy in non-small cell lung cancer (NSCLC) remains controversial. The introduction of immune checkpoint inhibitors (ICIs) has revolutionised the treatment of stage IV NSCLC. While ICI combined with chemotherapy (ChT) leads to longer duration of response and higher response rates compared with ChT alone, it can also cause serious adverse events (AEs) resulting in treatment discontinuation. In case of treatment discontinuation due to AEs after partial response to systemic treatment, surgical treatment of residual disease can be considered as it could lead to complete response. We present a case of a patient with stage IV NSCLC who is currently alive without any signs of cancer after partial response to ICI/ChT followed by surgical removal of residual disease.
Competing Interests: Competing interests: None declared.
(© BMJ Publishing Group Limited 2022. No commercial re-use. See rights and permissions. Published by BMJ.)
Competing Interests: Competing interests: None declared.
(© BMJ Publishing Group Limited 2022. No commercial re-use. See rights and permissions. Published by BMJ.)